Bioventus Inc.
BVS
$7.72
$0.081.05%
NASDAQ
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.35% | -4.31% | 13.45% | 15.04% | 10.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.35% | -4.31% | 13.45% | 15.04% | 10.32% |
| Cost of Revenue | -4.22% | -0.63% | 3.79% | 8.27% | -0.77% |
| Gross Profit | -1.49% | -6.02% | 18.95% | 18.64% | 16.29% |
| SG&A Expenses | -6.02% | -6.72% | 10.43% | 16.07% | 12.46% |
| Depreciation & Amortization | -30.28% | -9.23% | -15.89% | -10.88% | -10.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.33% | -4.29% | 7.29% | 13.01% | 7.42% |
| Operating Income | 39.27% | -4.79% | 330.66% | 79.50% | 53.71% |
| Income Before Tax | 124.82% | 37.58% | 102.76% | 41.01% | -855.31% |
| Income Tax Expenses | 114.18% | -110.47% | 173.33% | -1.83% | -2,026.25% |
| Earnings from Continuing Operations | 127.10% | 47.94% | 95.85% | 38.33% | -623.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -121.24% | -54.06% | -89.62% | -59.88% | 712.86% |
| Net Income | 129.04% | 46.07% | 97.44% | 33.94% | -597.69% |
| EBIT | 39.27% | -4.79% | 330.66% | 79.50% | 53.71% |
| EBITDA | 15.76% | -1.00% | 71.18% | 7.92% | 13.38% |
| EPS Basic | 127.99% | 48.32% | 97.52% | 36.40% | -581.80% |
| Normalized Basic EPS | -57.33% | 23.64% | 177.53% | 72.06% | 2,071.08% |
| EPS Diluted | 127.44% | 48.32% | 97.52% | 36.40% | -581.80% |
| Normalized Diluted EPS | -58.62% | 23.64% | 177.53% | 72.06% | 2,071.08% |
| Average Basic Shares Outstanding | 3.81% | 4.15% | 3.73% | 3.87% | 2.41% |
| Average Diluted Shares Outstanding | 6.99% | 4.15% | 3.73% | 3.87% | 2.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |